Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer

Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer

Multimodality treatment provides modest survival benefits for patients with locally advanced (stage III) non-small-cell lung cancer (NSCLC). Nevertheless, preoperative immunotherapy has continuously been shown to be promising in treating resectable NSCLC.This phase 2 trial enrolled patients with AJC...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ze-Rui Zhao, Chao-Pin Yang, Si Chen, Hui Yu, Yong-Bin Lin, Yao-Bin Lin, Han Qi, Jie-Tian Jin, Shan-Shan Lian, Yi-Zhi Wang, Jin-Qi You, Wen-Yu Zhai, Hao Long
Formato: article
Lenguaje:EN
Publicado: Taylor & Francis Group 2021
Materias:
lung cancer
neoadjuvant
immunotherapy
chemotherapy
toripalimab
Immunologic diseases. Allergy
RC581-607
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/d071f34e1bff4d239614d466b1517629
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/d071f34e1bff4d239614d466b1517629

Ejemplares similares